Diamond Biotechnology Co., Ltd

TPEX:6815 Stock Report

Market Cap: NT$2.5b

Diamond Biotechnology Past Earnings Performance

Past criteria checks 5/6

Diamond Biotechnology has been growing earnings at an average annual rate of 21.8%, while the Medical Equipment industry saw earnings growing at 9.6% annually. Revenues have been growing at an average rate of 24.9% per year. Diamond Biotechnology's return on equity is 10.9%, and it has net margins of 9.5%.

Key information

21.8%

Earnings growth rate

18.6%

EPS growth rate

Medical Equipment Industry Growth11.5%
Revenue growth rate24.9%
Return on equity10.9%
Net Margin9.5%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Diamond Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TPEX:6815 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 247086720235
31 Mar 246625719932
31 Dec 236164719629
30 Sep 235774616927
30 Jun 235384614225
31 Mar 234874012725
31 Dec 224353311226
30 Sep 224354810728
30 Jun 224356410231
31 Mar 224155310729
31 Dec 213954211228
30 Sep 213531911820
30 Jun 21311-412312
31 Mar 2130931177
31 Dec 20306111113
30 Sep 20295201023
30 Jun 2028329942
31 Mar 2027637862
31 Dec 1926844771
31 Dec 1822841494
31 Dec 1719342420

Quality Earnings: 6815 has high quality earnings.

Growing Profit Margin: 6815's current net profit margins (9.5%) are higher than last year (8.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 6815's earnings have grown significantly by 21.8% per year over the past 5 years.

Accelerating Growth: 6815's earnings growth over the past year (46.1%) exceeds its 5-year average (21.8% per year).

Earnings vs Industry: 6815 earnings growth over the past year (46.1%) exceeded the Medical Equipment industry 1.7%.


Return on Equity

High ROE: 6815's Return on Equity (10.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 13:42
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Diamond Biotechnology Co., Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution